SCHEMBL4349451

SCHEMBL4349451

Cc1noc(C)c1COc1ccc(C[C@H]2[C@@H](CN(CC(C)C)S(=O)(=O)c3ccc4c(c3)OCO4)OC(C)(C)N2C(=O)O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.41
KMT2A Q03164 3/20 0.41
PKM P14618 1/20 0.41
MAPT P10636 4/20 0.41
MEN1 O00255 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 2/20 0.40
ALDH1A1 P00352 3/20 0.39
ALOX15 P16050 1/20 0.39
ABCB1 P08183 1/20 0.39
LMNA P02545 3/20 0.38
HTT P42858 1/20 0.38
GAA P10253 1/20 0.36
POLB P06746 1/20 0.36
ESR2 Q92731 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HPGD P15428 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353115 0.89 ABCB1 (0.38) TSHRKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL4347227 0.88 ADAMTS4 (0.46) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL4352479 0.88 MMP13 (0.40) KMT2AMEN1SMN1; SMN2MAPK1ALDH1A1
SCHEMBL13630996 0.86 ABCB1 (0.52) TSHRKMT2APKMMAPTMEN1
SCHEMBL6051092 0.86 ABCB1 (0.52) TSHRKMT2APKMMAPTMEN1
SCHEMBL4347715 0.86 LMNA (0.40) TSHRKMT2AMAPTMEN1SMN1; SMN2
SCHEMBL4353025 0.86 ADAMTS4 (0.40) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL4340869 0.86 LMNA (0.40) TSHRKMT2AMAPTMEN1SMN1; SMN2
SCHEMBL4345112 0.86 LMNA (0.40) TSHRKMT2AMAPTMEN1SMN1; SMN2
SCHEMBL4341082 0.86 LMNA (0.40) TSHRKMT2AMEN1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 TSHR 4851/4885KMT2A 864/4885PKM 2752/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 TSHR 4851/4885KMT2A 864/4885PKM 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.